PMID- 33446845
OWN - NLM
STAT- MEDLINE
DCOM- 20210810
LR  - 20210810
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 11
IP  - 1
DP  - 2021 Jan 14
TI  - Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin 
      for type 2 diabetes patients at high cardiovascular risk.
PG  - 1430
LID - 10.1038/s41598-020-80753-9 [doi]
LID - 1430
AB  - We aimed to compare the (1) clinical outcomes including composite cardiovascular 
      outcomes, cardiovascular death, and all-cause death, and (2) healthcare costs of 
      using liraglutide and basal insulin as an initial treatment for patients with 
      type 2 diabetes mellitus (T2DM) and high cardiovascular diseases (CVD) risk. This 
      is a retrospective cohort study using Taiwan's Health and Welfare Database. A 
      total of 1057 patients treated with liraglutide were identified and matched with 
      4600 patients treated with basal insulin. The liraglutide group had a lower risk 
      of a composite CVD outcome (hazard ratio (HR) 0.65; 95% confidence interval (CI) 
      0.50-0.85; p < 0.01), all-cause mortality (HR 0.40; 95% CI 0.28-0.59; 
      p < 0.0001), and nonfatal stroke (HR 0.54; 95% CI 0.34-0.87; p = 0.01). Compared 
      to the basal insulin group, the liraglutide group had lower median 
      per-patient-per-month (PPPM) inpatient, emergency room (ER), and total medical 
      costs, but higher median PPPM outpatient, total pharmacy, and total costs (all 
      p < 0.0001). In conclusion, compared to basal insulin, liraglutide was found to 
      be associated with reduced risk of a composite CVD outcome, nonfatal stroke, and 
      all-cause mortality among high CVD risk patients with T2DM. In addition, 
      liraglutide users had lower inpatient, ER, and total medical costs, but they had 
      higher outpatient and total pharmacy costs.
FAU - Huang, Wan-Chun
AU  - Huang WC
AD  - School of Pharmacy, College of Pharmacy, Taipei Medical University, No.250, 
      Wuxing St., Taipei, 11031, Taiwan.
FAU - Chen, Yen-Chou
AU  - Chen YC
AD  - Division of Cardiovascular Medicine, Department of Internal Medicine, Wan Fang 
      Hospital, Taipei Medical University, Taipei, Taiwan.
FAU - Wu, Chung-Hsuen
AU  - Wu CH
AD  - School of Pharmacy, College of Pharmacy, Taipei Medical University, No.250, 
      Wuxing St., Taipei, 11031, Taiwan.
FAU - Ko, Yu
AU  - Ko Y
AD  - School of Pharmacy, College of Pharmacy, Taipei Medical University, No.250, 
      Wuxing St., Taipei, 11031, Taiwan. nancykotw@gmail.com.
AD  - Research Center for Pharmacoeconomics, College of Pharmacy, Taipei Medical 
      University, Taipei, Taiwan. nancykotw@gmail.com.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20210114
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 4FT78T86XV (Insulin Detemir)
RN  - 839I73S42A (Liraglutide)
SB  - IM
MH  - Aged
MH  - *Cardiovascular Diseases/drug therapy/economics/mortality
MH  - *Diabetes Mellitus, Type 2/drug therapy/economics/mortality
MH  - Female
MH  - *Health Care Costs
MH  - Humans
MH  - *Insulin Detemir/administration & dosage/economics
MH  - *Liraglutide/administration & dosage/economics
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Taiwan/epidemiology
PMC - PMC7809152
COIS- The authors declare no competing interests.
EDAT- 2021/01/16 06:00
MHDA- 2021/08/11 06:00
PMCR- 2021/01/14
CRDT- 2021/01/15 05:56
PHST- 2020/10/15 00:00 [received]
PHST- 2020/12/28 00:00 [accepted]
PHST- 2021/01/15 05:56 [entrez]
PHST- 2021/01/16 06:00 [pubmed]
PHST- 2021/08/11 06:00 [medline]
PHST- 2021/01/14 00:00 [pmc-release]
AID - 10.1038/s41598-020-80753-9 [pii]
AID - 80753 [pii]
AID - 10.1038/s41598-020-80753-9 [doi]
PST - epublish
SO  - Sci Rep. 2021 Jan 14;11(1):1430. doi: 10.1038/s41598-020-80753-9.